cas 821791-69-9|| where to buy 4-ethyl-2-fluoroaniline

Produktname:4-ethyl-2-fluoroaniline

IUPAC Name:4-ethyl-2-fluoroaniline

Packungseinheit	Verfügbarer Vorrat	Preis($)
CM123910-100mg	in stock	ǶǶ
CM123910-250mg	in stock	ƥƿȡ
CM123910-1g	in stock	ƿƿŵ
CM123910-5g	1-2 Weeks	ƥƿȐƥ

Nur für den Einsatz in Forschung und Entwicklung..

Anfrage-Formular

Chemische Bezeichnung

CAS-Nummer

Menge*

Erforderliche Spezifikationen*
(Gehalt %, Materialqualität etc.)

Name des Ansprechpartners*

E-Mail des Ansprechpartners*

Meanwhile I'd like to create a registered account on CHEMENU.COM with the above email.

I'd like to receive emails related to products with similar structures to 821791-69-9 regularly via the above email.

Zusätzliche Hinweise

Verification code*

refresh

: CAS-Nr.:821791-69-9; Molekulare Formel:C8H10FN; Schmelzpunkt:-; SMILES-Code:NC1=CC=C(CC)C=C1F; Dichte:

: Katalognummer:CM123910; Molekulargewicht:139.17; Siedepunkt:196.7±20.0°C at 760 mmHg; Mdl-Nr.:; Lagerung:Keep in dark place, store at 2-8°C.

: Benzenes; Benzene is an important organic compound with the chemical formula C6H6, and its molecule consists of a ring of 6 carbon atoms, each with 1 hydrogen atom. Benzene is a sweet, flammable, colorless and transparent liquid with carcinogenic toxicity at room temperature, and has a strong aromatic odor. It is insoluble in water, easily soluble in organic solvents, and can also be used as an organic solvent itself. The ring system of benzene is called benzene ring, and the structure after removing one hydrogen atom from the benzene ring is called phenyl. Benzene is one of the most important basic organic chemical raw materials. Many important chemical intermediates can be derived from benzene through substitution reaction, addition reaction and benzene ring cleavage reaction.

: Navacaprant; Navacaprant, a novel and selective kappa opioid receptor(KOR) antagonist, has no agonist properties implicated in opioid-related abuse.
Navacaprant is a potent KOR antagonist currently in clinical development for the treatment of neurobehavioral disorders, including Phase 3 clinical trials in adults with major depressive disorder. Navacaprant demonstrates high affinity and selectivity for the human KOR over the human MOR and DOR and exhibits reversible antagonist activity at KOR ex vivo and in vivo.